The role of disodium pamidronate in the management of bone pain due to malignancy

Palliative Medicine

Volumn 15, Issue 4, 2001, Pages 297-307

  Groff, L ^a   Zecca, E ^a   De Conno, F ^a   Brunelli, C ^a   Boffi, R ^a   Panzeri, C ^a   Cazzaniga, M ^a   Ripamonti, Carla ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Advanced cancer patients; Bone metastases; Disodium pamidronate; Pain; Palliative treatment

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PARACETAMOL;

ADULT; ADVANCED CANCER; ANALGESIA; ANALYSIS; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; DRUG TOLERABILITY; DRUG USE; EVALUATION; FEMALE; FEVER; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORTHOPEDICS; PAIN ASSESSMENT; PHLEBITIS; POPULATION RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TERMINAL DISEASE;

ADULT; AGED; ANALGESICS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES;

EID: 0034937667     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/026921601678320287     Document Type: Article

References (32)

1. Pain in far-advanced cancer
2. Metastatic bone disease: Clinical and therapeutical aspects
3. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
4. Malignant bone pain: Pathophysiology and treatment
5. Malignant bone pain: Pathophysiology and treatments
6. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
7. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial
8. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
9. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study
10. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
11. High dose pamidronate: Clinical and biochemical effects in metastatic bone disease
12. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
13. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized, controlled trial
14. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
15. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate infusions
16. Bisphosphonates - Mechanisms of action
17. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials
18. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
19. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
20. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1, 1-bisphosphonic acid on the development of tumour osteopathies in the rat: Experimental studies with the Walker carcinosarcoma 256
21. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
22. Bisphosphonates inhibit prostate and breast cancer carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
23. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
24. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
25. Pharmacology and clinical efficacy of bisphosphonates
26. Uveitis associated with pamidronate
27. Pamidronate disodium and possible ocular adverse drug reactions
28. The clinical course of bone metastases from breast cancer
29. Different doses of pamidronate in patients with painful osteolytic bone metastases
30. Current use of bisphosphonates in oncology
31. Bisphosphonates for metastatic bone pain